Data Article

Dataset of KCNQ1, KCNN4, KATP channel expression and dexamethasone modulation of protein kinase signaling in airway epithelial cells

Darina Hynes, Brian J. Harvey

A Department of Molecular Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland
b Centro di Estudios Científicos CECs, Valdivia, Chile

Article history:
Received 23 July 2019
Received in revised form 1 October 2019
Accepted 1 October 2019
Available online 22 October 2019

Keywords:
Dexamethasone
Non-genomic
Airway epithelium
KCNQ1
KCNN4
KATP channels
Protein kinases

Abstract
Dexamethasone produces anti-secretory responses in airway epithelium through the inhibition of basolateral membrane K⁺ channels [1–3]. We have used the human bronchial epithelial cell line 16HBE14o− to investigate the effects of dexamethasone on the expression of K⁺ channels and regulatory protein kinases. The data demonstrate the expression of three distinct K⁺ channel types – KCNQ1:KCNE3, KCNN4 and KATP which are differentially regulated by protein kinase A and protein kinase C. The data also provide evidence for rapid non-genomic actions of dexamethasone on the expression of K⁺ channel sub-types. Biotinylation experiments provide data on the effects of dexamethasone on membrane expression of the K⁺ channels. Antibody co-immunoprecipitation, rtPCR and western blotting data are given for the non-genomic dexamethasone transcription–cell signaling pathway involving Gᵢ-protein coupled receptor, PKC, adenylyl cyclase Type IV, cAMP, PKA and ERK1/2 activation.

© 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Specifications table

| Subject | Endocrinology |
|---------|---------------|
| Specific subject area | Dexamethasone regulation of airway epithelial K\(^+\) channels |
| Type of data | Tables |
| How data were acquired | RT-PCR, western blotting, antibody co-immunoprecipitation, biotinylation |
| Data format | Raw Analysed |
| Parameters for data collection | For the data reported here, 16HBE14o\(^-\) cells were plated in 75 cm\(^2\) polystyrene culture flasks and grown to confluence in Eagle's Minimum Essential Medium (EMEM) supplemented with 10% foetal bovine serum, 1% non-essential amino acids, 1% L-glutamine, 50 U/ml penicillin, 0.05 mg/ml streptomycin. Western blot analysis was carried out as standard. Protein was transferred to nitrocellulose membranes, blocked in 1\(\times\) TBS with Tween (0.3%) (1 \(\times\) TBST) and 5% non-fat dry milk for 1 h. Membranes were incubated with the appropriate primary antibody overnight at 4 \(\circ\)C and incubated for 1 h at room temperature with the appropriate secondary antibody. Membranes were washed in 1 \(\times\) TBST 0.3% three times for 15 min. Bands were detected using autoradiographic film and chemiluminescence. Human KCNQ1 (hKCNQ1) cloned into pTLN6, was kindly provided by Prof. Thomas Jentsch (Leibniz-Institute for Molecular Pharmacology, Berlin, Germany). Cell surface labelling with biotin-LC-hydrazide: Confluent 16HBE14o\(^-\) cell monolayers were washed three times with ice cold PBS-CM (PBS supplemented with 1 mM MgCl\(_2\) and 0.1 mM CaCl\(_2\)) and sodium periodate in PBS-CM added at a concentration of 10 mM for 30 minutes. After removal of the sodium periodate, the monolayers were washed twice with PBS-CM and three times with 0.1 M sodium acetate-CM (0.1 M sodium acetate (pH 5.5) supplemented with 1 mM MgCl\(_2\), 0.1 mM CaCl\(_2\), 0.1 mM biotin–LC–hydrazide (0.37 mg/ml made up in ice-cold Na acetate-CM, pH 5.5) was added to the cells for a further 30 minutes. Termination of the labelling was brought about by removal of the biotin with subsequent washing of the monolayers three times in PBS. Cells were solubilised by the addition of 0.5 ml/well lysate buffer and incubation at 4 \(\circ\)C for 1 hour on a rotating wheel. Insoluble material was pelleted by centrifugation for 15 minutes at 14,000 rpm and the supernatant removed to fresh microfuge tubes. Protein concentrations of samples were calculated by comparison to the BSA standards. Specific proteins were immunoprecipitated by incubating the extracts with 20 \(\mu\)l protein-G Sepharose beads. Cell surface biotin-labelled proteins were identified by incubation of the membrane with horseradish peroxidase (HRP)-conjugated streptavidin for 60 minutes at room temperature and visualisation detected by an enhanced chemiluminescent procedure (ECL-plus). |
| Description of data collection | Densitometric analysis of western blots and PKA, PKC assays were performed using Gene tools software (Syngene, Cambridge UK). Background was subtracted from each densitometric value. Statistical analysis of the data was performed using a t-test for comparison between two groups. One-way ANOVA and Tukeys post-hoc test was used for multiple group analyses. P-values of 0.05 and less were considered to be significant. Statistical operations were performed using Excel\(^\circ\) software (Microsoft) and GraphPad\(^\circ\) InStat version 3.5 (GraphPad Software, San Diego). Data are expressed as means \(\pm\) SEM. Number of samples (n) refers to the number of times the independent experiments were performed. |
| Data source location | RCSI-ERC, Beaumont Hospital City/Region: Dublin Country: Ireland Latitude and longitude: 53.3902738, -6.2209754 |
| Data accessibility | With this article Related research article Author's name Darina Hynes and Brian J. Harvey Title Dexamethasone reduces airway epithelial Cl\(^-\) secretion by rapid non-genomic inhibition of KCNQ1, KCNN4 and KATP K\(^+\) channels Journal Steroids Special Issue RRSH2018 DOI |

Value of the Data

- Data demonstrate non-genomic regulation of K\(^+\) channels and protein kinases by dexamethasone in airway epithelial cells.
- Data provide insights into steroid regulation of epithelial ion channels via protein kinases.
- Data provide insights into molecular mechanisms of non-genomic actions of glucocorticoids.
- Data are useful in assessing clinical use of glucocorticoids to modulate hypersecretion in asthma and COPD.
1. Data

We have previously described a rapid non-genomic anti-secretory effect of corticosteroids on airway Cl⁻ secretion via inhibition of basolateral membrane K⁺ channels [1–3]. Here we present the original data underpinning these findings.

2. Experimental design, materials, and methods

2.1. Expression of the KCNN4 protein in 16HBE14o⁻ airway epithelial cells

Western blot analysis was performed to determine expression of the KCNN4 channel in 16HBE14o⁻ cells. Primers specific for KCNN4 (GenBank accession No. AF000972) were designed using the Primer 3 software (Table 1). A PCR product of the expected size was generated from complimentary DNA extracted from 16HBE14o⁻ cells (Fig. 1). The T84 cell line was used as a positive control. As illustrated in Fig. 2, an anti-KCNN4 antibody recognized prominent bands with the molecular masses of 46 kDa.

2.2. Membrane expression of KCNN4 in 16HBE14o⁻ cells

Biotinylation experiments were performed to investigate the effect of dexamethasone on the expression and membrane localization of KCNN4 channels (Fig. 3). The presence of KCNN4 at the basolateral membrane was confirmed by cell surface biotinylation. However, no change in surface expression of KCNN4 following dexamethasone (15mins, 1 nM) or vehicle (15mins, methanol, 0.001% v/v) treatment was observed.

Table 1

| Protein | Primer Sequence 5’ → 3’ | Product size bp |
|---------|------------------------|----------------|
| KCNN4 (F) | GCCGTGCCTGCAGGATTTAGG | 403 |
| KCNN4 (R) | GCCCGGCACCACGTCACCATA | |
| GAPDH (F) | CATTGGGGGTAGGAACACGGA | 373 |
| GAPDH(R) | GCCAAAAGGGTCATCATCTCGG | |

Fig. 1. Semi-quantitative RT-PCR analysis of KCNN4 expression in 16HBE14o⁻ cells. Total RNA was isolated from 16HBE14o⁻ cells using RNA easy kit (Qiagen). cDNA was reverse transcribed using poly dT primers and ImProm™ Reverse Transcriptase System (Promega, USA) and 1 μl of this reaction was directly amplified using GoTaq® Green Master Mix (Promega, USA) using specific primers for human KCNN4 isoform and synthesised by MWG Biotech (Germany). The PCR reaction produced DNA fragments at the expected length for KCNN4 in T84 and 16HBE14o⁻ cells. GAPDH (cDNA and GAPDH primer pairs) was used as a control and neg (negative control, primers pairs without cDNA).
Fig. 2. **KCNN4 protein expression in 16HBE14o− cells.** Western blot analysis of KCNN4 proteins in human bronchial epithelial cells. Total protein (100 μg/lane) was transferred to nitrocellulose membrane after fractionating by SDS-PAGE and blotted with anti-KCNN4. Bands at 46 kDa corresponding to KCNN4 were detected. β-actin was used as a control to estimate protein loading. Values represent mean ± SEM, n = 3; n.s. denotes values were not significant between T84 and 16HBE14o− samples. Statistical analysis was performed using the Student’s paired t-test.

Fig. 3. **KCNN4 channels are present at the membrane in 16HBE14o− cells.** Representative Western blot of biotin-labelled cell surface KCNN4 protein. Dexamethasone (1nM) or vehicle (methanol, 0.001% v/v) was added to 16HBE14o− cells for 15 mins. Barchart summary for the effect of dexamethasone on cell surface biotinylation in 16HBE14o− cells. Values are mean ± SEM, n = 3, n.s. denotes values are not significant. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparison tests.
Table 2
Oligonucleotide sequences of human KCNQ1 and GAPDH primers used for RT-PCR. HKCNQ1 primers were designed using the Primer 3 program.

| Protein  | Primer Sequence 5' → 3' | Product size bp |
|----------|-------------------------|-----------------|
| KCNQ1 (F) | ATCTGGCTAGCTGCCAAAC | 272             |
| KCNQ1 (R) | TAGCTCAAACCTGATGCGG |                |
| GAPDH (F) | CATTGGGGGTAGGAACGGA  | 373             |
| GAPDH (R) | GCCAAAAGGGTCATCATCTCGG|                |

Fig. 4. Expression of KCNQ1 channel in 16HBE14o− cells. Semi-quantitative RT-PCR analysis of KCNQ1 expression in 16HBE14o− cells was amplified using specific primers for human KCNQ1, pRTLN-KCNQ1 (used as a positive control), ctl (negative control using hKCNQ1 primer pairs without cDNA), GAPDH (cDNA and GAPDH primer pairs) was used as a control.

Fig. 5. KCNQ1 and KCNE3 are expressed in 16HBE14o− cells. Western blot analysis of the KCNQ1 and KCNE3 proteins in 16HBE14o− cells. Total protein (100 µg/lane) was transferred to nitrocellulose membrane after fractioning by SDS-PAGE and blotted with anti-KCNQ1 or anti-KCNE3. β-actin was used as a control to estimate protein loading.
Table 3
Oligonucleotide sequences of primers used for K\textsubscript{ATP} channel RT-PCR.

| Protein  | Primer Sequence 5’ → 3’ | Product size bp |
|----------|--------------------------|-----------------|
| Kir 6.1(F) | GCCAGAAAGAGTATCATCCCGGAG | 352             |
| Kir 6.1(R) | CATTCCACTTTTCTCCATGTAAGC |                |
| Kir 6.2(F) | ATGCTGTCCCCGAAGGCGATC | 360             |
| Kir 6.2(R) | TAGTCACCTGGACCTCAATGGAG |                |
| SUR1 (F)  | CGATGCCATCACACAGAAG | 340             |
| SUR1(R)   | CTGAGGACCTCTCTGGCTT |                |
| SUR2A (F) | GCTGAAGAATATGGTCAAATCTC | 355             |
| SUR2A (R) | TGGAGTGTCATTTTCTAAAAA |                |
| GAPDH (R) | GCCAAAAGGGTCTCATCTCCG | 373             |
| GAPDH (F) | CATTGGGGGTAGGAACGGA |                |

Fig. 6. Agarose gel showing RT-PCR products amplified from 16HBE14o\textsuperscript{-} cDNA with PCR primer pairs for Kir6.1, Kir 6.2, SUR1, SUR2A and GAPDH. Semi-quantitative RT-PCR analysis of Kir6.1, Kir 6.2, SUR1, SUR2A and GAPDH expression in human bronchial epithelial cells was amplified using specific human primers.

Fig. 7. The KCNQ1 channel expression at the basolateral membrane in 16HBE14o\textsuperscript{-} cells. Representative Western blot of labelling cell surface KCNN4 proteins with Biotin-LC-hydrazide. Dexamethasone (1nM) and vehicle control (methanol, 0.001% v/v) were added to 16HBE14o\textsuperscript{-} cells for 15 mins. Bar chart summary for the effect of dexamethasone on cell surface biotinylation in 16HBE14o\textsuperscript{-} cells. Values are mean ± SEM; n.s. denotes that values were not significant compared to control values. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparison tests.
2.3. Expression of KCNQ1 channels in 16HBE14o/C0 airway epithelial cells

Semi-quantitative RT-PCR was carried out to determine expression of KCNQ1. Different primer pairs, designed to specifically amplify human KCNQ1 was used to generate PCR products from cDNAs of 16HBE14o/C0 cells (Table 2). Human KCNQ1 (hKCNQ1) cloned into pTLN6, was kindly provided by Prof. Thomas Jentsch (Leibniz-Institute for Molecular Pharmacology, Berlin, Germany), and was used as a positive control for KCNQ1 expression. Agarose gels showing RT-PCR products amplified from 16HBE14o/C0 cells with PCR primer pairs for hKCNQ1. Fig. 4 shows that the hKCNQ1 product was detected in 16HBE14o/C0 cells. Western blot analysis was performed to determine expression of the KCNQ1 channel and its regulatory subunit KCNE3 in 16HBE14o/C0 cells (Fig. 5). As illustrated, anti-KCNQ1 and anti-KCNE3 antibodies recognized prominent bands with the molecular masses of 37 kDa and 27 kDa respectively. The T84 cell line was used as a positive control as these cells are known to express KCNQ1 protein. These data confirm that the cAMP-dependent KCNQ1 channels and their KCNE3 regulatory subunit are expressed in 16HBE14o/C0 cells.

2.4. Expression of KATP channels in 16HBE14o/C0 epithelial cells

The molecular identity of the lung KATP channel subunits was investigated in the 16HBE14o− cells. Different primer pairs, designed to specifically amplify human Kir 6.1, Kir 6.2, SUR 1 and SUR 2A (Table 3) were used to generate PCR products from cDNAs of 16HBE14o− cells. The Kir 6.1 and Kir 6.2 primer pairs amplified bp products, respectively (Fig. 6). In addition, the SUR 1 primer pairs...
amplified a 340 bp product. No product could be detected with primers for SUR2A. These results suggest that the K<sub>ATP</sub> channels in 16HBE14o<sup>-</sup> cells could be formed from Kir 6.1, Kir 6.2 and SUR2A subunits. The sulfonylurea receptors SUR 2A and subunits Kir 6.1 and Kir 6.2 were found to be expressed in the 16HBE14o<sup>-</sup> cell line.

Fig. 9. PKC<sub>α</sub>, PKC<sub>δ</sub>, PKC<sub>ε</sub> and PKD1 (PKC<sub>μ</sub>) are expressed in 16HBE14o<sup>-</sup> cells. Representative Western blot analysis of PKC subunits: PKC<sub>α</sub> (A), PKC<sub>δ</sub> (B), PKC<sub>ε</sub> (C) and PKD1 (D) in cellular extracts of 16HBE14o<sup>-</sup> and MCF-7 cells. Total protein (50 μg/lane) was transferred to nitrocellulose membranes after fractionating by SDS-PAGE and blotted with anti-PKC antibodies. β-actin (42 kDa) was used as an internal control to estimate protein loading. The graphs represent densitometric analysis of PKC expression. Values are given as reflective PKC expression in 16HBE14o<sup>-</sup> cell lysates compared to MCF-7. Values are displayed as mean ± SEM (n = 3). ** Denotes p < 0.001, * denotes p < 0.01, n.s. denotes not significant (p > 0.05) between PKC isoform in MCF-7 and 16HBE14o<sup>-</sup>. Statistical analysis was performed using the Students paired t-test.
2.5. Cell surface expression of KCNQ1

Biotinylation experiments were performed to investigate the effect of dexamethasone on the localization of the KCNQ1 channel. The presence of KCNQ1 at the membrane was confirmed by cell surface biotinylation (Fig. 7). There was no change in surface expression of KCNQ1 following dexamethasone (1 nM) or vehicle (0.001% methanol) treatment indicating that dexamethasone does not change the cellular localization or expression of the KCNQ1 channel.

2.6. Effects of dexamethasone on expression and activation of PKC isoforms in human bronchial epithelial cells

Candidate protein kinase C isoforms of the cPKC and the nPKC groups were investigated in mediating the rapid anti-secretory responses to dexamethasone. Primers specific for PKCα, PKCδ, PKCε and

| Treatment                  | PKCα activation (phosphorylation at Ser 657) |
|----------------------------|---------------------------------------------|
| Lysate control             | 1 ± 0                                       |
| Dexamethasone (1nM, 2 min) | 5.12 ± 1.9                                  |
| Dexamethasone (1nM, 5 min) | 1.95 ± 0.39                                 |
| Dexamethasone (1nM, 10 min)| 3.84 ± 0.39                                 |
| Dexamethasone (1nM, 15 min)| 2.05 ± 0.56                                 |
| Methanol (0.001% v/v, 2 min)| 1.79 ± 0.33                                 |
| Methanol (0.001% v/v, 5 min)| 1.81 ± 0.20                                 |
| Methanol (0.001% v/v, 10 min)| 1.40 ± 0.16                                 |
| Methanol (0.001% v/v, 15 min)| 1.05 ± 0.34                                |
PKD were designed using the Primer 3 program. PCR products of the expected size were generated from cDNA extracted from 16HBE14o−/C0 cells (Table 4, Fig. 8).

2.7. Expression of PKC isoforms in human bronchial epithelial cells

The results obtained from RT-PCR analysis were confirmed by western blotting. Western blots were performed on three independently derived cell lysates to establish PKC isoform expression. As a positive control lysates from MCF-7 breast cancer cell line was used. Western blot analysis revealed expression of these selected isoforms in 16HBE14o− cells. An equivalent amount of protein (50 µg) was loaded in each track and equal loading of samples was confirmed by probing the same blot with β-actin monoclonal antibody.

ImmunobLOTS using antibodies for individual isoforms of PKC were performed: PKCα (Fig. 9A), PKCδ (Fig. 9B), PKCe (Fig. 9C) and PKD (Fig. 9D) in 16HBE14o− cells and MCF-7 cells. Western blot analysis

Table 6
Summary of the fold increases in PKCδ activity.

| Treatment         | PKCδ activation (phosphorylation at Ser 643) |
|-------------------|---------------------------------------------|
| Lysate control    | 1.1 ± 0.27                                  |
| Dexamethasone (1nM, 2 min) | 1.46 ± 0.36                             |
| Dexamethasone (1nM, 5 min) | 1.69 ± 0.27                             |
| Dexamethasone (1nM, 10 min) | 1.67 ± 0.32                            |
| Dexamethasone (1nM, 15 min) | 2.09 ± 0.32                            |
| Methanol (0.001% v/v, 2 min) | 1.74 ± 0.26                             |
| Methanol (0.001% v/v, 5 min) | 1.89 ± 0.40                             |
| Methanol (0.001% v/v, 10 min) | 1.78 ± 0.46                             |
| Methanol (0.001% v/v, 15 min) | 1.65 ± 0.31                             |
| Control           | 1.43 ± 0.28                                 |
| Bombesin          | 4.03 ± 0.12                                 |

PKD were designed using the Primer 3 program. PCR products of the expected size were generated from cDNA extracted from 16HBE14o− cells (Table 4, Fig. 8).

2.7. Expression of PKC isoforms in human bronchial epithelial cells

The results obtained from RT-PCR analysis were confirmed by western blotting. Western blots were performed on three independently derived cell lysates to establish PKC isoform expression. As a positive control lysates from MCF-7 breast cancer cell line was used. Western blot analysis revealed expression of these selected isoforms in 16HBE14o− cells. An equivalent amount of protein (50 µg) was loaded in each track and equal loading of samples was confirmed by probing the same blot with β-actin monoclonal antibody.

ImmunobLOTS using antibodies for individual isoforms of PKC were performed: PKCα (Fig. 9A), PKCδ (Fig. 9B), PKCe (Fig. 9C) and PKD (Fig. 9D) in 16HBE14o− cells and MCF-7 cells. Western blot analysis
revealed the expression of the classical isoform PKCa (80 kDa), the novel isoforms PKCd (78 kDa) and PKCe (95 kDa) and also expression of PKD (115 kDa). PKCa and PKD1 were expressed in equal quantities in 16HBE14o− cells compared to MCF-7 cells (positive control). PKCd and PKCe were significantly (**p < 0.001, *p < 0.01) respectively, less expressed in 16HBE14o− cells compared to MCF-7 control. This reflected non-uniform expression of PKC isoform levels (PKCa > PKD1 > PKCe > PKCd levels of expression).

2.8. Effect of dexamethasone on PKCa, PKCd and PKCe activity in 16HBE14o− cells

The levels of PKC isoform activation can be observed through changes in phosphorylation states at key amino acid residues. For PKCa activation Ser657 autophosphorylation in the hydrophobic C-terminal is required for catalytic activation and stabilisation of the protein upon translocation to the plasma membrane. PKCd activity was assessed using an antibody to PKCd phosphorylated at Ser643. PKCd autophosphorylates at Ser643 in the turn motif after initial phosphorylation at Thr505 by PDK-1.

### Table 7
Summary of the fold increase in PKCe activity induced by dexamethasone.

| Treatment               | PKCe activation (phosphorylation at Ser 729) |
|-------------------------|---------------------------------------------|
| Lysate control          | 1 ± 0                                       |
| Dexamethasone (1nM, 2 min) | 1.5 ± 0.31                                 |
| Dexamethasone (1nM, min)  | 1.45 ± 0.24                                |
| Dexamethasone (1nM, 10 min) | 1.27 ± 0.15                               |
| Dexamethasone (1nM, 15 min) | 1.26 ± 0.13                               |
| Methanol (0.001% v/v, 2 min) | 1.22 ± 0.11                               |
| Methanol (0.001% v/v, 5 min) | 1.25 ± 0.12                               |
| Methanol (0.001% v/v, 10 min) | 1.29 ± 0.05                               |
| Methanol (0.001% v/v, 15 min) | 1.22 ± 0.11                               |
| Bombesin               | 3.54 ± 0.24                                |
| Control                | 1.71 ± 0.17                                |
in the activation loop. PKC\(\varepsilon\) activation requires phosphorylation at three sites (1): Thr666 in the activation loop (2), Ser729 in the C-terminal hydrophobic region and (3) autophosphorylation at Thr710. The level of phosphorylation at these residues can be used as a measure of catalytic activity of the kinase isoforms. By employing antibodies specific to the phosphorylated form of PKCs, activation was monitored in response to dexamethasone by Western blot analysis.

PKC\(\alpha\) activation was assessed by probing with a specific antibody to phosphorylation at Ser 657. Dexamethasone treatment produced a biphasic activation of PKC\(\alpha\) at 2 and 10 mins (Fig. 10, Table 5).

PKC\(\delta\) activity was measured using a specific antibody to phosphorylation at Ser643. Dexamethasone treatment had no effect on PKC\(\delta\) phosphorylation levels (Fig. 11, Table 6). PKC\(\varepsilon\) activity was measured

**Table 8**

List of primers for human adenylyl cyclase isoforms AC1-9 and GAPDH.

| Protein | Primer Sequence 5' → 3' | Product size bp | GenBank Accession No. |
|---------|--------------------------|-----------------|----------------------|
| AC1 (F) | CATGACCTGGGAGGAGCAT      | 446             | L05500               |
| AC1 (R) | ACAGGAGACTCGGAATCTGAA     | 369             | X74210               |
| AC2 (R) | CAGGAACCCGACAGGATA        | 263             | NM_004036            |
| AC3 (F) | CACGGGACCACCGAAT          | 287             | AF088070             |
| AC4 (R) | GCGAGTGGCAATCTCAGC        | 163             | U65473               |
| AC5 (F) | ACCAAAGCTACACTCACTAC      | 380             | AB007882             |
| AC6 (R) | AGCGTTATCTTGGCGATCA       | 359             | NM_001114            |
| AC7 (F) | TTAGCAGATGATGAAAACAGACTT  | 497             | NM_001116            |
| AC8 (F) | CCGTATTTGGCAGGCTCTA       | 287             | AF088070             |
| AC9 (R) | CACGGCAGCTCCAGATGCTGAGCC  | 359             | NM_001114            |
| GAPDH (F) | CATTGGGGGTAGGAACTCCG     | 373             | X02231               |
| GAPDH (R) | GCCAAAAGGGTACATCTCTCCG   |                 |                      |

**Fig. 13. Semi-quantitative RT-PCR analysis of adenylyl cyclase isoforms AC1-9 in human bronchial epithelial cells.** Total RNA was isolated from 16HBE14o cells using RNA easy kit (Qiagen). cDNA was reverse transcribed using poly dT primers and ImProm\textsuperscript{TM} Reverse Transcriptase System (Promega, USA) and 1 \(\mu\)l of this reaction was directly amplified using GoTaq\textsuperscript{®} Green Master Mix. (Promega, USA) using specific primers for human AC isoforms (Xu, D, Isaaca, C (2001)) (Table 3) and synthesised by MWG Biotech (Germany). The PCR reaction produced DNA fragments at the expected length for AC 3, 4, 6 and 7. (+) denotes GAPDH and (−) denotes negative control. Figure representative of three independent experiments.
using a specific antibody to phosphorylation at Ser 729. Dexamethasone treatment had no effect on PKCε phosphorylation levels (Fig. 12, Table 6). Bombesin was used as a positive control for PKC activation. Stripping the blot and reprobing with β-actin showed equal loading of all lanes. These results show that dexamethasone selectively activates classical PKCa and does not rapidly activate the novel PKC isoforms: PKCd and PKCe.

2.9. Expression of cAMP-adenyl cyclase-PKA signaling pathway in 16HBE14o− cells

Adenylyl cyclase (AC) expression was determined in 16HBE14o− cells. Because of the unavailability of satisfactory antibodies for most of the AC isoforms, the expression of AC isoforms was investigated by RT-PCR (Table 8). As shown in Fig. 13, the AC isoforms AC3, AC4, AC6 and AC7 were found to be expressed in 16HBE14o− cells.

2.10. Expression of PKA regulatory and catalytic subunits in human bronchial epithelial cells

Since AC isoforms are expressed in 16HBE14o− cells, it was of interest to investigate the expression levels of the catalytic and regulatory subunits of PKA in 16HBE14o− cells. The PKA isoform I (PKAI) the soluble cytosolic isoform, was investigated in cellular extracts in this study, as distinct from isoform II which is membrane bound. Total untreated cellular lysates of 16HBE14o− cells were prepared and subjected to western blot analysis by probing with specific antibodies to endogenous levels of PKA regulatory (PKAR1) and catalytic (PKAC1) subunits. As shown in Fig. 14, 16HBE14o− cells express equal levels of both PKAR1 and PKAC1 subunits compared with MCF-7 cells used as a positive control. Expression differences were normalized for loading by probing for total β-actin levels.
2.11. Dexamethasone effects on cAMP-dependent protein kinase A activity

The cAMP-adenyl-kinase pathway is clearly expressed in 16HBE14o− cells. We therefore examined the effects of dexamethasone on PKA activity. To determine the time course of dexamethasone activation of PKA in 16HBE14o− cells, serum starved cells were exposed to dexamethasone (1 nM) or equivalent vehicle (methanol, 0.001% v/v) for the duration of 2, 5 and 10 mins. PKA activity was rapidly and dramatically upregulated after 5 mins in response to dexamethasone (1 nM) treatment and

![Fig. 15. PKA is rapidly activated in response to dexamethasone in 16HBE14o− cells. A: The graph represents densitometric analysis at specific time points of dexamethasone treatment. Values are given as fold changes in PKA phosphorylation of the F-Kemptide PepTag for 16HBE14o− cell lysates. Values are displayed as mean ± SEM (n = 6). ** Denotes significance (p < 0.001) between control and treated values. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparison tests. B: Representative image of PKA activation of an F-Kemptide PepTag in cellular extracts from 16HBE14o− cells. PKA activity phosphorylated the F-Kemptide PepTag peptide changing its net charge from +1 to −1. This allows the phosphorylated and non-phosphorylated forms of the substrate to be rapidly separated on agarose gel. Lane 1, lysate control, Lane 2, forskolin (20 μM/5 min), Lane 3, dexamethasone (1 nM, 2 min), Lane 4, dexamethasone (1 nM, 5 min), Lane 5, dexamethasone (1 nM, 10 min), Lane 6, vehicle control (methanol 0.001% v/v/2 min), Lane 7, vehicle control (methanol 0.001% v/v, 5 min), Lane 8, vehicle control (methanol 0.001% v/v, 10 min).

Table 9

Summary of the fold increases in PKA activity following dexamethasone treatment.

| Treatment                        | Fold increase in PKA activity |
|----------------------------------|------------------------------|
| Forskolin (20 μM, 5 min)         | 3.4 ± 0.81                   |
| Dexamethasone (1 nM, 0 min)      | 1 ± 0                        |
| Dexamethasone (1 nM, 2 min)      | 1.03 ± 0.05                  |
| Dexamethasone (1 nM, 5 min)      | 2.6 ± 0.35                   |
| Dexamethasone (1 nM, 10 min)     | 0.93 ± 0.17                  |
| Methanol (0.001% v/v, 2 min)     | 0.87 ± 0.25                  |
| Methanol (0.001% v/v, 5 min)     | 1.04 ± 0.05                  |
| Methanol (0.001% v/v, 10 min)    | 1.05 ± 0.08                  |

2.11. Dexamethasone effects on cAMP-dependent protein kinase A activity
returned to basal levels after 10 mins (Fig. 15). The effect was comparable to forskolin (20 μM) a well-known activator of AC. A summary of the fold increases in PKA activity for each treatment is shown in Table 9.

2.12. PKA and cAMP effects on cAMP-dependent protein kinase activity

The adenylyl cyclase activator, forskolin, and the PKA antagonist, Rp-cAMP[S], were used as positive and negative controls for PKA stimulation, respectively. Dexamethasone increased PKA activity and this effect was inhibited by Rp-cAMP[S] (Fig. 16). The effect was comparable to forskolin, a known activator of adenylyl cyclase. Table 10 shows a summary of fold increases in PKA activity.

2.13. Dexamethasone induces rapid non-genomic PKA activation

The rapid time course (5 minutes) of the dexamethasone effect on PKA activity suggests that this response does not involve a classical genomic mechanism. In order to verify this hypothesis we
investigated the dexamethasone response in the presence of cycloheximide, an inhibitor of mRNA translation. Dexamethasone (1 nM) stimulated a 2.62 \pm 0.29-fold increase in total PKA activity in 16HBE14o−/C0 cells after 5 min (Fig. 17). This increase was not inhibited by preincubation with cycloheximide (1 \mu M) for 1 hour. The vehicle control and cycloheximide alone did not stimulate a significant change in PKA activity relative to untreated control. Table 11 shows a summary for the fold changes in

| Treatment | Fold increase in PKA activity |
|-----------|------------------------------|
| Forskolin (20 \mu M, 5 min) | 2.39 \pm 0.30 |
| Dexamethasone (1 nM, 5 min) | 2.97 \pm 0.07 |
| Dexamethasone (1 nM, 5 min) + Rp-cAMP[S] (20 \mu M, prior treatment 40 min) | 1.75 \pm 0.13 |
| Lysate control | 1.1 \pm 0.07 |
| Methanol (0.001% v/v, 5 min) | 0.92 \pm 0.51 |

Fig. 17. Dexamethasone induces PKA activity independent of translation. A: The graph represents densitometric analysis of treatments. Values are given as fold changes in PKA activity measured as phosphorylation of the F-Kemptide PepTag for 16HBE14o− cell lysates. Values are displayed as mean \pm SEM (n = 4), n.s. denotes not significance (p > 0.05) between dexamethasone and dexamethasone and inhibitor treated values. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparison tests. B: UV-illuminated agarose gel of the products of reactions run with F-Kemptide and 16HBE14o− homogenate. Lane 1, dexamethasone (1 nM, 5 min) Lane 2, cycloheximide (prior treatment 1 \mu M/60 min) and dexamethasone, (1 nM, 5 min) Lane 3, vehicle control (methanol, 0.001% v/v, 5 min), Lane 4, methanol, 0.001% v/v 5 min and cycloheximide.
Table 11
Summary of the fold increases in PKA activity.

| Treatment                                                                 | Fold increase in PKA activity |
|---------------------------------------------------------------------------|------------------------------|
| Dexamethasone (1 nM, 5 min)                                              | 2.62 ± 0.29                  |
| Dexamethasone (1 nM, 5 min) + cycloheximide (1 μM, 60 min prior treatment) | 2.9 ± 0.27                   |
| Methanol (0.001% v/v, 5 min)                                             | 1.2 ± 0.26                   |
| Methanol (0.001% v/v, 5 min) + cycloheximide (1 μM, 60 min prior treatment) | 1.77 ± 0.21                  |

Fig. 18. Dexamethasone induces PKA activity independent of the classical GR and MR receptor antagonists. A: The graph represents densitometric analysis at specific time points of dexamethasone treatment. Values are given as fold changes in PKA activity measured as phosphorylation of the F-Kemptide PepTag for 16HBE14o− cell lysates. Values are displayed as mean ± SEM (n = 4). n.s. denotes not significant between dexamethasone and dexamethasone and inhibitor treated values. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparison tests. B: UV-illuminated agarose gel of the products of reactions run with F-Kemptide and 16HBE14o− homogenate. Lane 1, lysate control, Lane 2, dexamethasone (1 nM, 5 min), Lane 3, RU486 (prior treatment 1 μM/30 min) and dexamethasone (1 nM, 5 min), Lane 4, vehicle control (methanol, 0.001% v/v, 5 min), Lane 5, RU486 + vehicle control (methanol 0.001% v/v, 5 min), Lane 6, dexamethasone (1 nM, 5 min), Lane 7, spironolactone (prior treatment 10 μM/30 min) and dexamethasone, (1 nM, 5 min), Lane 8, spironolactone + vehicle control (methanol 0.001% v/v, 5 min).

Table 12
Summary of the fold increases in PKA activity.

| Treatment                                                                 | Fold increase in PKA activity |
|---------------------------------------------------------------------------|------------------------------|
| Lysate control (1 nM, 5 min)                                              | 1.0 ± 0                       |
| Dexamethasone (1 nM, 5 min)                                              | 2.35 ± 0.17                  |
| Dexamethasone (1 nM, 5 min) + RU486 (1 μM, 30 min prior treatment)        | 2.48 ± 0.20                  |
| Methanol (0.001% v/v, 5 min)                                             | 1.24 ± 0.16                  |
| Methanol (0.001% v/v, 5 min) + RU486 (1 μM)                               | 1.52 ± 0.11                  |
| Dexamethasone (1 nM, 5 min)                                              | 2.37 ± 0.25                  |
| Dexamethasone + spironolactone (10 μM, 30 min prior treatment)            | 2.37 ± 0.33                  |
| Methanol (0.001% v/v, 5 min) + spironolactone (10 μM)                     | 1.49 ± 0.21                  |
PKA activity. This result indicates that the dexamethasone induced increase in PKA activity observed after 5 min treatment is not dependent on changes in gene translation.

2.14. Role of MR and GR in dexamethasone PKA response? - Effect of the classic glucocorticoid antagonist, RU486 and the mineralocorticoid antagonist, spironolactone on dexamethasone-induced PKA activity

In order to investigate the receptor involved in the rapid response to dexamethasone, RU486 and spironolactone were used as antagonists of the GR and the MR, respectively. In control experiments the receptor antagonists did not affect basal PKA activity. Furthermore, neither RU486 nor spironolactone

Table 13
Summary of the fold increases in PKA activity.

| Treatment | Fold increase in PKA activity |
|-----------|-------------------------------|
| Forskolin (20 μM, 5 min) | 2.97 ± 0.24 |
| Dexamethasone (1nM, 5 min) | 1.9 ± 0.17 |
| Dexamethasone (1 nM, 5 min) + PD98059 (50 μM, 30 min prior treatment) | 1.68 ± 0.09 |
| Dexamethasone (1 nM, 5 min) + PTX (2 μg/l, 20 min prior treatment) | 1.18 ± 0.20 |
| Methanol (0.001% v/v, 5 min) | 1 ± 0 |
treatment significantly affected the dexamethasone induced PKA activation in 16HBE14o− cells (Fig. 18, Table 12). Taken together, these data indicate the rapid effect of dexamethasone on PKA activity in human airway epithelial cells is a non-genomic response that does not involve the nuclear GR or MR receptors.

2.15. Role of pertussis toxin sensitive G protein-coupled receptors in the PKA response to dexamethasone

The role of G protein-coupled receptors (GPCRs) in the rapid response to dexamethasone was investigated using pertussis toxin (PTX). As shown in Fig. 19 and Table 13, PKA activity was up-regulated in less than 5 min by 40% over control (p < 0.01) following 1 nM dexamethasone treatment. The Gi protein inhibitor, PTX (2 μg/l) significantly inhibited the activation of PKA by dexamethasone. The cells pretreated with PTX before dexamethasone did not show a significantly increased phosphorylation compared with untreated control cells (p > 0.1). In contrast, the MEK 1 inhibitor, PD98059 (50 μM), had no significant effect on PKA activation by the steroid (p > 0.1). In these experiments, the AC activator, forskolin, and the PKA antagonist, (Rp)-cAMP, were used as positive and negative controls for PKA stimulation, respectively. The vehicle control (methanol 0.001% v/v) did not stimulate PKA activity. These data suggest a role for a PTX sensitive G protein-coupled receptor in the rapid PKA response to dexamethasone.

Fig. 20. ERK1/2 MAPK is expressed in 16HBE14o− cells. A: The graph represents densitometric analysis of MAPK expression. Values are given as fold changes in ERK1/2 MAPK expression in MCF-7 and 16HBE14o−cell lysates. Values are displayed as mean ± SEM (n = 3). Statistical analysis: Student’s paired t-test. B: Representative Western blot analysis of ERK1/2 MAPK in cellular extracts of 16HBE14o− and MCF-7 cells. Total protein (30 μg/lane) was transferred to nitrocellulose membranes after fractionating by SDS-PAGE and blotted with anti-ERK1/2 MAPK. β-actin (42 kDa) was used as an internal control to estimate protein loading.
2.16. Activation of the ERK1/2 MAPK pathway by dexamethasone

PKA is known to activate downstream ERK1/2 MAPK signaling to induce non-genomic responses to steroid hormones. The basal expression level of ERK1/2 MAPK in 16HBE14o−/C0 cells was examined. Total untreated cellular lysates of 16HBE14o−/C0 cells were prepared, subjected to western blot analysis and probed using a specific antibody recognising ERK1/2 MAPK. Expression differences were normalized for loading by probing for total β-actin levels. MCF-7 cells were used as a positive control as they are known to express ERK1/2 MAPK. This result clearly showed that ERK1/2 MAPK was expressed in 16HBE14o−/C0 cells (Fig. 20).

2.17. Dexamethasone activation of ERK1/2 MAPK

The effect of dexamethasone on the activation of ERK1/2 MAPK was next examined. Phosphorylation of ERK1/2 MAPK on key threonine 202 and tyrosine 204 residues is strongly correlated with an increased activation of these kinases.

An antibody specific for phospho-ERK1/2 MAPK was used to determine phosphorylation in response to dexamethasone by western blot analysis. As shown in Fig. 21, dexamethasone (1 nM) produced a biphasic activation of ERK1/2 MAPK. ERK1/2 activation was observed as early as 2 minutes reaching a maximal activation at 10 minutes, thereafter returning to basal levels by 15 minutes. Dexamethasone treatment increased ERK1/2 MAPK phosphorylation levels compared to vehicle controls (Table 14). In 16HBE14o− cells the rapid activation of ERK1/2 MAPK occurs in a time frame consistent with the rapid activation of PKA by dexamethasone.

2.18. Non-genomic response - dexamethasone induces ERK1/2 MAPK activation independent of mRNA translation

The time course (5 minutes) of the dexamethasone effect on ERK1/2 MAPK activity suggests that this response does not involve a classical genomic mechanism. In order to verify this hypothesis we...
tested the dexamethasone (1 nM) response in the presence of cycloheximide, an inhibitor of mRNA translation. As shown in Fig. 22, the increase in ERK1/2 MAPK activity following dexamethasone treatment was not reduced by preincubation with cycloheximide (1 μM) (Table 15). EGF (100 ng/ml) was used as a positive control for MAPK activation. These results indicate a mechanism of dexamethasone-induced activation of ERK1/2 MAPK that is independent of de novo protein synthesis.

**Table 14**

Summary of the fold increases in ERK1/2 MAPK activity induced by dexamethasone.

| Treatment                                      | Fold increase in ERK1/2 MAPK activity |
|------------------------------------------------|---------------------------------------|
| Lysate control                                 | 1 ± 0                                 |
| Dexamethasone (1 nM, 2 min)                    | 3.08 ± 0.26                          |
| Dexamethasone (1 nM, 5 min)                    | 2.17 ± 0.4                           |
| Dexamethasone (1 nM, 10 min)                   | 5.83 ± 0.23                          |
| Dexamethasone (1 nM, 15 min)                   | 1.6 ± 0.53                           |
| Methanol (0.001% v/v, 2 min)                   | 0.85 ± 0.12                          |
| Methanol (0.001% v/v, 5 min)                   | 0.93 ± 0.17                          |
| Methanol (0.001% v/v, 10 min)                  | 0.89 ± 0.14                          |
| Methanol (0.001% v/v, 15 min)                  | 1.6 ± 0.53                           |

**Fig. 22. Dexamethasone induces ERK1/2 MAPK activation independent mRNA translation.**

A: The graph represents densitometric analysis at specific time points of dexamethasone treatment. Values are given as fold changes in ERK1/2 activation of 16HBE14o− cell lysates. Values are displayed as mean ± SEM (n = 3); n.s. denotes not significant between dexamethasone and dexamethasone and inhibitor treated values. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparison tests.

B: Representative Western blot analysis of phospho-ERK1/2 MAPK in cellular extracts of 16HBE14o−. The effect of inhibiting translation on the dexamethasone induced MAPK activation was determined by Western blot. Lane 1, lysate control, Lane 2, dexamethasone (1 nM, 5 min), Lane 3, Cycloheximide (prior treatment 1 μM/60 min) and dexamethasone (1 nM, 5 min), Lane 4, vehicle control (methanol, 0.001% v/v, 5 min), Lane 5, vehicle control (methanol 0.001% v/v, 5 min), Lane 6, EGF (100 ng/ml, 10 min).
2.19. Dexamethasone PKA activation is upstream of MAPK activation

The potential role of PKA in dexamethasone-induced activation of ERK 1/2 MAPK was examined. As shown in Fig. 23, dexamethasone (1 nM) stimulated ERK1/2 MAPK phosphorylation in 16HBE14o cells (p < 0.001) (lane 2). The rapid activation of MAPK by dexamethasone was significantly inhibited (p < 0.001) by the PKA inhibitor H89 (10 μM) (lane 4) demonstrating that PKA is activated upstream of ERK1/2 MAPK. As an internal control the MEK 1 inhibitor PD98059 (25 μM) (lane 5) inhibited the ERK1/2 MAPK activity. Table 16 shows a summary of fold increases in ERK1/2 MAPK activity.

Table 15
Summary of the fold increases in ERK1/2 MAPK activity induced by Dexa.

| Treatment                                                   | Fold increase in ERK1/2 MAPK activity |
|-------------------------------------------------------------|--------------------------------------|
| Lysate control                                              | 1 ± 0                                 |
| Dexamethasone (1 nM, 10 min)                                | 2.44 ± 0.53                          |
| Dexamethasone (1 nM, 10 min) + cycloheximide (1 μM, 60 min prior treatment) | 2.17 ± 0.4                           |
| Methanol (0.001% v/v, 10 min)                               | 1.21 ± 0.24                          |
| Methanol (0.001% v/v, 10 min) + cycloheximide (1 μM)        | 1.74 ± 0.32                          |
| EGF (100 ng/ml, 10 min)                                     | 4.54 ± 1.63                          |

2.19. Dexamethasone PKA activation is upstream of MAPK activation

The potential role of PKA in dexamethasone-induced activation of ERK 1/2 MAPK was examined. As shown in Fig. 23, dexamethasone (1 nM) stimulated ERK1/2 MAPK phosphorylation in 16HBE14o− cells (p < 0.001) (lane 2). The rapid activation of MAPK by dexamethasone was significantly inhibited (p < 0.001) by the PKA inhibitor H89 (10 μM) (lane 4) demonstrating that PKA is activated upstream of ERK1/2 MAPK. As an internal control the MEK 1 inhibitor PD98059 (25 μM) (lane 5) inhibited the ERK1/2 MAPK activity. Table 16 shows a summary of fold increases in ERK1/2 MAPK activity.

Fig. 23. Effect of the PKA inhibitor, H89 and the MEK1 inhibitor, PD98059 on dexamethasone-induced ERK 1/2-activation. A: The graph represents densitometric analysis at specific time points of dexamethasone treatment. Values are given as fold changes in ERK1/2 activation of 16HBE14o− cell lysates. Values are displayed as mean ± SEM (n = 3); ** denotes values were significant (p < 0.001) between dexamethasone and dexamethasone and inhibitor treated values. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparison tests. B: Representative Western blot analysis of phospho-ERK1/2 MAPK in cellular extracts of 16HBE14o−.16HBE14o− cells were treated with lysate control (Ctl) (lane 1), dexamethasone 1nM (lane 2), vehicle control (methanol, 0.001%) (lane 3), dexamethasone (1 nM) after pretreatment with PD98059 (25 μM, 20 mins) (lane 4), dexamethasone (1 nM) after pretreatment with H89 (10 μM, 20 mins) (lane 5). Effect of methanol on inhibitor pre-treatment of PD98059 (lane 6) and H89 (lane 7).
2.20. PKC activation is upstream of PKA

The data indicate that dexamethasone induced MAP kinase activation is dependent on upstream PKA activity. What dexamethasone modulated kinase, if any, is upstream of PKA?

| Treatment                                                   | Fold increase in ERK1/2 MAPK activity |
|--------------------------------------------------------------|--------------------------------------|
| Lysate control                                              | 1 ± 0                                |
| Dexamethasone (1 nM, 10 min)                                 | 4.0 ± 1.4                            |
| Methanol (0.001% v/v, 10 min)                                | 1.4 ± 0.35                           |
| Dexamethasone (1 nM, 10 min) + PD98059 (50 μM, 20 min pre-treatment) | 1.8 ± 0.7                            |
| Dexamethasone (1 nM) + H89 (10 μM, 20 min pre-treatment)     | 0.8 ± 0.20                           |
| PD98059 (50 μM) + methanol (0.001% v/v)                      | 0.73 ± 0.26                          |
| H89 (10 μM) + methanol (0.001% v/v)                          | 1.65 ± 0.36                          |

Fig. 24. PKA activated in response to dexamethasone and is downstream of PKC α. The graph represents densitometric analysis of treatments. Values are given as fold changes in PKA activation measured as phosphorylation of the F-Kemptide PepTag for 16HBE14o− cell lysates. Values are displayed as mean ± SEM (n = 3), * denotes (p > 0.01) between dexamethasone and dexamethasone plus PKC α inhibitor. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparison tests. UV-illuminated agarose gel of the products of reactions run with F-Kemptide and 16HBE14o− homogenate. Lane 1, lysate control; Lane 2, dexamethasone (1 nM, 5 min); Lane 3, HBDDE (prior treatment 100 μM/40 min) and dexamethasone (1 nM, 5 min) Lane 4, vehicle control (methanol, 0.001% v/v, 5 min), Lane 5, methanol 0.001% v/v, 5 min and vehicle control (DMSO 0.1% v/v) for HBDDE.
In order to determine whether PKC activation was involved in the dexamethasone induced activation of PKA, the effects of the PKCα inhibitor 2,2',3,3',4,4'-Hexahydroxy-1,1'-biphenyl-6,6'-dimethanol Dimethyl Ether (HBDDE), a selective inhibitor of PKCα and PKCγ (IC50 concentration: PKCα, 43 μM and PKCγ 50 μM) was examined. PKCγ was not expressed in the human airway epithelial cells (it is

### Table 17
Summary of the fold increases in PKA activity.

| Treatment                                                                 | Fold increase in PKA activity |
|---------------------------------------------------------------------------|-------------------------------|
| Lysate control                                                            | 1 ± 0                         |
| Dexamethasone (1nM, 5 min)                                                | 2.15 ± 0.12                   |
| Dexamethasone (1 nM, 5 min) + HBDDE (100 μM, 30 min prior treatment)      | 1.36 ± 0.18                   |
| Methanol (0.001% v/v, 5 min)                                              | 1.35 ± 0.08                   |
| Methanol (0.001% v/v, 5 min) + HBDDE (100 μM, 30 min prior treatment)     | 1.34 ± 0.05                   |

### Table 18
Summary of the fold increases in PKD activity.

| Treatment                                                                 | PKD activation (phosphorylation at Ser 729) |
|---------------------------------------------------------------------------|---------------------------------------------|
| Lysate control                                                            | 2.27 ± 0.26                                 |
| Dexamethasone (1nM, 2 min)                                                | 1.7 ± 0.27                                  |
| Dexamethasone (1nM, 5 min)                                                | 1.64 ± 0.32                                 |
| Dexamethasone (1nM, 10 min)                                               | 2.19 ± 0.32                                 |
| Dexamethasone (1nM, 15 min)                                               | 1.78 ± 0.26                                 |
| Methanol (0.001% v/v, 2 min)                                              | 1.96 ± 0.06                                 |
| Methanol (0.001% v/v, 5 min)                                              | 1.13 ± 0.13                                 |
| Methanol (0.001% v/v, 10 min)                                             | 2.11 ± 0.30                                 |
| Methanol (0.001% v/v, 15 min)                                             | 1.92 ± 1.16                                 |
| Bombesin                                                                  | 4.13 ± 0.31                                 |
| Control                                                                   | 1.4 ± 0.29                                  |

**Fig. 25. Dexamethasone does not activate PKD1 in 16HBE14o − cells.** Representative western blot analysis of phospho-PKD1 in cellular extracts of 16HBE14o −. By employing antibodies specific to the phosphorylated form of PKD1 (Ser 916), the activation by dexamethasone was monitored by Western blot analysis. β-actin (42 kDa) was used as an internal control to estimate protein loading. The graph represents densitometric analysis at specific time points of dexamethasone treatment. Bombesin (BOM) was used as a positive control for PKD1 activity. Values are given as fold changes in PKCε activation of 16HBE14o − cell lysates. Values are displayed as mean ± SEM (n = 3); n.s. denotes no significance between control and treated values. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparison tests.

In order to determine whether PKC activation was involved in the dexamethasone induced activation of PKA, the effects of the PKCα inhibitor 2,2',3,3',4,4'-Hexahydroxy-1,1'-biphenyl-6,6'-dimethanol Dimethyl Ether (HBDDE), a selective inhibitor of PKCα and PKCγ (IC50 concentration: PKCα, 43 μM and PKCγ 50 μM) was examined. PKCγ was not expressed in the human airway epithelial cells (it is
exclusively expressed in brain and spinal tissue). Dexamethasone induced PKA activation was calculated as fold increases (arbitrary units, A.U.). Serum starved cells were treated with HBDDE (100 μM) for 30 mins before dexamethasone treatment (1 nM). Vehicle and HBDDE on its own had no effect on basal PKA activity. However, pretreatment with the PKCα inhibitor HBDDE (100 μM) prevented dexamethasone induced PKA activation (Fig. 24, Table 17). This result shows that PKA activated in response to dexamethasone is downstream of PKCα.

2.21. Effect of dexamethasone on PKD1 activation in 16HBE14o− cells

Protein kinase D is a potential downstream target of cPKC and nPKCs. To determine whether dexamethasone stimulated activation of PKD1 in 16HBE14o− cells, serum starved cells were treated with dexamethasone (1 nM) and PKD1 activity was assessed by probing with an antibody specific to phosphorylation to Ser916. Residue Ser916 is a site of autophosphorylation in the PKD1 structure that occurs subsequent to phosphorylation at Ser744/748 by PKC. Phosphorylation at Ser916 is therefore indicative of PKD activation. Treatment of 16HBE14o− cells with dexamethasone had no significant effect on PKD1 phosphorylation levels (Fig. 25, Table 18). Bombesin was used as a positive control as it is known to activate PKD1.

Acknowledgments

This work was supported by the Higher Education Authority of Ireland PRTLI4 grant, National Biophotonics Imaging Platform Ireland.

Conflict of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] V. Urbach, V. Verriere, Y. Grumbach, J. Bousquet, B.J. Harvey, Rapid anti-secretory effects of glucocorticoids in human airway epithelium, Steroids 71 (4) (2006 Apr) 323–328.
[2] V. Urbach, D.E. Walsh, B. Mainprice, J. Bousquet, B.J. Harvey, Rapid non-genomic inhibition of ATP-induced Cl− secretion by dexamethasone in human bronchial epithelium, J. Physiol. 545 (3) (2002 Dec 15) 869–878.
[3] D. Hynes, B.J. Harvey, Dexamethasone reduces airway epithelial Cl− secretion by rapid non-genomic inhibition of KCNQ1, KCNN4 and KATP K+ channels, Steroids 151 (2019 Nov) 108459, https://doi.org/10.1016/j.steroids.2019.108459, Epub 2019 Jul.